胸腺肽治疗重症肺炎合并脓毒血症的临床疗效探讨

Observation on the Clinical Effect of Thymosin in Treatment of Severe Pneumonia Complicated with Sepsis

目的探讨胸腺肽治疗重症肺炎合并脓毒血症的临床疗效。方法整群2014年1月—2015年1月该院收治的重症肺炎并脓毒血症患者76例作为研究对象。采用随机数表法将其分为观察组与对照组,每组38例,其中对照组在常规抗感染与支持治疗基础上进行皮下注射安慰剂,观察组在常规治疗基础上进行皮下注射胸腺肽,比较两组患者各项临床指标及临床疗效。结果观察组患者血管活性药停用时间、休克逆转时间等明显低于对照组,并且治疗后血清炎症因子水平低于对照组,P<0.05,差异具有统计学意义;治疗后观察组患者治疗总有效率明显高于对照组,P<0.05,差异具有统计学意义。结论胸腺肽皮下注射治疗重症肺炎合并脓毒血症临床疗效确切,可显著改善患者机体炎症反应,降低休克反应发生率等,具有临床应用及推广价值。

Objective To investigate the clinical effect of thymosin in treatment of severe pneumonia complicated with sep-sis. Methods 76 cases of patients with severe pneumonia complicated with sepsis admitted to this hospital from January 2014 to January 2015 were screened as the research object, and they were divided into observation group and control group with 38 in each one according to the random number table method. All the patients underwent conventional anti-infection and supportive treatment, based on which the control group received subcutaneous placebo injection and the observation group underwent subcutaneous thymosin injection. The clinical indexes and curative effect of the patients were compared between the two groups. Results Vasoactive drug withdrawal and reversion of shock were both significantly earlier, and level of serum inflammatory cytokines after treatment was lower in the observation group than in the control group, and the dif-ferences were statistically significant, P〈0.05; the total effective rate was obviously higher in the observation group than in the control group after treatment, and the difference was statistically significant, P〈0.05. Conclusion The clinical effect of subcutaneous thymosin injection in the treatment of severe pneumonia complicated with sepsis is exact： it can significantly improve patients＇ inflammatory response and reduce the shock incidence. Therefore, this method is worthy of clinical appli-cation and promotion.